Compare Sanofi India with Glenmark Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

SANOFI INDIA vs GLENMARK PHARMA - Comparison Results

SANOFI INDIA     Change

Sanofi India (the erstwhile Aventis Pharma), the 60% subsidiary of Sanofi-Aventis SA, France, is one of the largest pharma MNCs in India with a turnover of over Rs 13.2 bn in CY11. Domestic sales constituted 81% of total sales in CY11 and exports con... More

GLENMARK PHARMA 
   Change

Glenmark's focus areas are dermatology, gynecology, pediatrics and diabetics. The domestic formulations business contributed about 35% to revenues in FY07. On the international front, besides exports to the semi-regulated markets, the company has bee... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    SANOFI INDIA GLENMARK PHARMA SANOFI INDIA/
GLENMARK PHARMA
 
P/E (TTM) x 41.0 16.5 249.0% View Chart
P/BV x 8.3 2.7 308.7% View Chart
Dividend Yield % 1.0 0.4 280.4%  

Financials

 SANOFI INDIA   GLENMARK PHARMA
EQUITY SHARE DATA
    SANOFI INDIA
Dec-18
GLENMARK PHARMA
Mar-19
SANOFI INDIA/
GLENMARK PHARMA
5-Yr Chart
Click to enlarge
High Rs6,840712 961.2%   
Low Rs4,630484 957.4%   
Sales per share (Unadj.) Rs1,203.1349.6 344.1%  
Earnings per share (Unadj.) Rs165.332.8 504.1%  
Cash flow per share (Unadj.) Rs209.944.3 473.4%  
Dividends per share (Unadj.) Rs84.002.00 4,200.0%  
Dividend yield (eoy) %1.50.3 437.6%  
Book value per share (Unadj.) Rs963.6198.6 485.1%  
Shares outstanding (eoy) m23.03282.17 8.2%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x4.81.7 278.9%   
Avg P/E ratio x34.718.2 190.4%  
P/CF ratio (eoy) x27.313.5 202.7%  
Price / Book Value ratio x6.03.0 197.8%  
Dividend payout %50.86.1 833.1%   
Avg Mkt Cap Rs m132,078168,625 78.3%   
No. of employees `0003.312.0 27.4%   
Total wages/salary Rs m4,06820,561 19.8%   
Avg. sales/employee Rs Th8,393.88,196.0 102.4%   
Avg. wages/employee Rs Th1,232.41,708.1 72.1%   
Avg. net profit/employee Rs Th1,153.0768.5 150.0%   
INCOME DATA
Net Sales Rs m27,70898,655 28.1%  
Other income Rs m8972,081 43.1%   
Total revenues Rs m28,605100,736 28.4%   
Gross profit Rs m6,23515,858 39.3%  
Depreciation Rs m1,0273,259 31.5%   
Interest Rs m73,346 0.2%   
Profit before tax Rs m6,09811,335 53.8%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m01,672 0.0%   
Tax Rs m2,2923,756 61.0%   
Profit after tax Rs m3,8069,250 41.1%  
Gross profit margin %22.516.1 140.0%  
Effective tax rate %37.633.1 113.4%   
Net profit margin %13.79.4 146.5%  
BALANCE SHEET DATA
Current assets Rs m15,92266,968 23.8%   
Current liabilities Rs m6,23540,211 15.5%   
Net working cap to sales %35.027.1 128.9%  
Current ratio x2.61.7 153.3%  
Inventory Days Days6483 76.4%  
Debtors Days Days2181 25.7%  
Net fixed assets Rs m7,53933,322 22.6%   
Share capital Rs m230282 81.5%   
"Free" reserves Rs m21,96255,770 39.4%   
Net worth Rs m22,19256,052 39.6%   
Long term debt Rs m035,738 0.0%   
Total assets Rs m29,839132,888 22.5%  
Interest coverage x872.14.4 19,877.5%   
Debt to equity ratio x00.6 0.0%  
Sales to assets ratio x0.90.7 125.1%   
Return on assets %12.89.5 134.8%  
Return on equity %17.216.5 103.9%  
Return on capital %27.517.8 154.4%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m7,58762,998 12.0%   
Fx outflow Rs m7,14522,859 31.3%   
Net fx Rs m44240,140 1.1%   
CASH FLOW
From Operations Rs m3,73913,242 28.2%  
From Investments Rs m-731-6,990 10.5%  
From Financial Activity Rs m-1,972-7,387 26.7%  
Net Cashflow Rs m1,036-2,971 -34.9%  

Share Holding

Indian Promoters % 0.0 48.3 -  
Foreign collaborators % 60.4 0.0 -  
Indian inst/Mut Fund % 14.4 6.9 208.7%  
FIIs % 14.6 34.4 42.4%  
ADR/GDR % 0.0 0.0 -  
Free float % 10.5 10.5 100.0%  
Shareholders   15,184 56,727 26.8%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare SANOFI INDIA With:   SHASUN PHARMA  WYETH  TORRENT PHARMA  SUVEN LIFE SCIENCES  DR. REDDYS LAB  

Compare SANOFI INDIA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex, Nifty Recover From Day's Low to End Strong; TCS & Wipro Rally Over 3.5%(Closing)

Indian share markets recouped early losses during closing hours and ended today's volatile session higher, helped by gains in metals and banking stocks.

Related Views on News

GLENMARK PHARMA Share Price Up by 5%; BSE HEALTHCARE Index Up 0.9% (Market Updates)

Apr 15, 2021 | Updated on Apr 15, 2021

GLENMARK PHARMA share price is trading up by 5% and its current market price is Rs 540. The BSE HEALTHCARE is up by 0.9%. The top gainers in the BSE HEALTHCARE Index is GLENMARK PHARMA (up 5.2%). The top losers are JUBILANT PHARMOVA (down 0.2%) and GSK PHARMA (down 0.3%).

SANOFI INDIA Announces Quarterly Results (2QFY21); Net Profit Up 5.0% (Quarterly Result Update)

Oct 29, 2020 | Updated on Oct 29, 2020

For the quarter ended September 2020, SANOFI INDIA has posted a net profit of Rs 1 bn (up 5.0% YoY). Sales on the other hand came in at Rs 7 bn (down 11.9% YoY). Read on for a complete analysis of SANOFI INDIA's quarterly results.

GLENMARK PHARMA Announces Quarterly Results (1QFY21); Net Profit Up 132.5% (Quarterly Result Update)

Sep 1, 2020 | Updated on Sep 1, 2020

For the quarter ended June 2020, GLENMARK PHARMA has posted a net profit of Rs 3 bn (up 132.5% YoY). Sales on the other hand came in at Rs 23 bn (up 0.9% YoY). Read on for a complete analysis of GLENMARK PHARMA's quarterly results.

SANOFI INDIA Announces Quarterly Results (1QFY21); Net Profit Up 39.9% (Quarterly Result Update)

Aug 26, 2020 | Updated on Aug 26, 2020

For the quarter ended June 2020, SANOFI INDIA has posted a net profit of Rs 1 bn (up 39.9% YoY). Sales on the other hand came in at Rs 7 bn (down 5.0% YoY). Read on for a complete analysis of SANOFI INDIA's quarterly results.

SANOFI INDIA Announces Quarterly Results (4QFY20); Net Profit Down 8.1% (Quarterly Result Update)

May 21, 2020 | Updated on May 21, 2020

For the quarter ended March 2020, SANOFI INDIA has posted a net profit of Rs 854 m (down 8.1% YoY). Sales on the other hand came in at Rs 8 bn (up 9.4% YoY). Read on for a complete analysis of SANOFI INDIA's quarterly results.

More Views on News

Most Popular

India: Recovery Stalled by Vaccine Games?(The Honest Truth)

Apr 13, 2021

Ajit Dayal on how India's vaccine strategy will impact the markets.

4 Stocks to Make Your Portfolio Immune to the Second Covid Wave(Profit Hunter)

Apr 6, 2021

Rather than predicting the market, successful investing is more about preparing well and placing your bets accordingly.

An India Revival Stock I'm Bullish On...(Profit Hunter)

Apr 9, 2021

This could take India to the position of 3rd largest economy.

Why Did the Market Crash on Monday?(Fast Profits Daily)

Apr 13, 2021

In this video, I'll you what I think is the real reason behind yesterday's market crash.

Why the Market Fell Yesterday(Fast Profits Daily)

Apr 6, 2021

In this video, I'll tell you the two reasons why the market fell on Monday and how you can prepare yourself for such events in the future.

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

SANOFI INDIA SHARE PRICE


Apr 15, 2021 (Close)

TRACK SANOFI INDIA

  • Track your investment in SANOFI INDIA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

SANOFI INDIA - ORCHID PHARMA COMPARISON

COMPARE SANOFI INDIA WITH

MARKET STATS